Research News – Personalized Cellular Immunotherapies 

We are excited to learn that Kite Pharma announced yesterday they will initiate personalized cellular immunotherapies before the end of 2016. These therapies will target certain sub-segments of the KRAS-mutant cancer patient population (KRAS-mutations are a biomarker of colorectal cancer). This new technology will use living immune cells as the…

Read Full Post

ASCO-2016: PRE CONFERENCE INSIGHTS

The American Society of Clinical Oncology (ASCO) annual meeting happens each June in Chicago. It is one of the premier meetings each year where oncologists, scientists and advocates gather to hear the latest clinical trial data in oncology, including focused sessions on GI cancers such…

Read Full Post

Know Your Biomarker :: August 2015 Webinar

ABOUT THE WEBINAR This event was hosted by advocacy organizations Fight Colorectal Cancer, Chris4Life, Colon Cancer Alliance, and sponsored by Amgen. “Personalized” medicine is an approach to individualize treatment plans. Steps can be taken to identify which treatments may be more or less beneficial to…

Read Full Post

Drinking Extra Orange Juice – Could It Kill Cancer?!

Since the 1970s, there has been interest in vitamin C’s potential to cure cancer – yes – the vitamin used in households nationwide to cure the common cold, the vitamin we see in enhanced beverages, the vitamin that is naturally stored not only in citrus…

Read Full Post

The Future of anti-EGFR Therapy? – Part 1

Last month in my blogs I discussed a few completely experimental CRC drug strategies in early phase clinical trials. Drug discovery isn’t all about venturing into the complete unknown however. Identifying ways to significantly improve current therapeutic strategies that have already been proven to help…

Read Full Post

July 2014 Webinar – The Latest News About CRC Research & Treatment

Learn the latest findings from the American Society of Clinical Oncology (ASCO) conference in May. The latest studies, treatments and developments and how they impact colorectal cancer patients were discussed. PRESENTED BY: Cathy Eng, M.D. Associate Professor, Department of Gastrointestinal (GI) Medical OncologyDr. Cathy Eng is Associate Professor…

Read Full Post

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in the future. We actively work…

Read Full Post

First-Line Treatment Approved for Stage IV Colorectal Cancer

There is new first-line treatment (standard of care to start treatment) giving as many as 60% of the stage IV colorectal cancer patients more options for treatment. Previously, most stage IV patients undergoing chemotherapy would be recommended to go on FOLFOX and bevacizumab (Avastin). Patients…

Read Full Post

Andi's Highlights on ASCO 2014

by Andi Dwyer, Director of Health Promotion, Fight Colorectal Cancer Working in the cancer prevention and survivorship field for nearly ten years, I was elated to attend my first ASCO.  However, nothing prepared me for the 35,000 people from throughout the world, gathered to unveil the…

Read Full Post
Page 1 of 3123